219 related articles for article (PubMed ID: 24347326)
1. Crystal structures of the fungal pathogen Aspergillus fumigatus protein farnesyltransferase complexed with substrates and inhibitors reveal features for antifungal drug design.
Mabanglo MF; Hast MA; Lubock NB; Hellinga HW; Beese LS
Protein Sci; 2014 Mar; 23(3):289-301. PubMed ID: 24347326
[TBL] [Abstract][Full Text] [Related]
2. Protein farnesyl transferase target selectivity is dependent upon peptide stimulated product release.
Troutman JM; Andres DA; Spielmann HP
Biochemistry; 2007 Oct; 46(40):11299-309. PubMed ID: 17877368
[TBL] [Abstract][Full Text] [Related]
3. Computational and conformational evaluation of FTase alternative substrates: insight into a novel enzyme binding pocket.
Henriksen BS; Zahn TJ; Evanseck JD; Firestine SM; Gibbs RA
J Chem Inf Model; 2005; 45(4):1047-52. PubMed ID: 16045300
[TBL] [Abstract][Full Text] [Related]
4. Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate.
Long SB; Casey PJ; Beese LS
Biochemistry; 1998 Jul; 37(27):9612-8. PubMed ID: 9657673
[TBL] [Abstract][Full Text] [Related]
5. Enzyme flexibility and the catalytic mechanism of farnesyltransferase: targeting the relation.
Sousa SF; Fernandes PA; Ramos MJ
J Phys Chem B; 2008 Jul; 112(29):8681-91. PubMed ID: 18572907
[TBL] [Abstract][Full Text] [Related]
6. Interplay of isoprenoid and peptide substrate specificity in protein farnesyltransferase.
Reigard SA; Zahn TJ; Haworth KB; Hicks KA; Fierke CA; Gibbs RA
Biochemistry; 2005 Aug; 44(33):11214-23. PubMed ID: 16101305
[TBL] [Abstract][Full Text] [Related]
7. The Aspergillus fumigatus farnesyltransferase β-subunit, RamA, mediates growth, virulence, and antifungal susceptibility.
Norton TS; Al Abdallah Q; Hill AM; Lovingood RV; Fortwendel JR
Virulence; 2017 Oct; 8(7):1401-1416. PubMed ID: 28489963
[TBL] [Abstract][Full Text] [Related]
8. Computational studies of the farnesyltransferase ternary complex part II: the conformational activation of farnesyldiphosphate.
Cui G; Merz KM
Biochemistry; 2007 Oct; 46(43):12375-81. PubMed ID: 17918965
[TBL] [Abstract][Full Text] [Related]
9. Finding a needle in the haystack: computational modeling of Mg2+ binding in the active site of protein farnesyltransferase.
Yang Y; Chakravorty DK; Merz KM
Biochemistry; 2010 Nov; 49(44):9658-66. PubMed ID: 20923173
[TBL] [Abstract][Full Text] [Related]
10. Exploiting the substrate tolerance of farnesyltransferase for site-selective protein derivatization.
Nguyen UT; Cramer J; Gomis J; Reents R; Gutierrez-Rodriguez M; Goody RS; Alexandrov K; Waldmann H
Chembiochem; 2007 Mar; 8(4):408-23. PubMed ID: 17279592
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities.
Hougland JL; Hicks KA; Hartman HL; Kelly RA; Watt TJ; Fierke CA
J Mol Biol; 2010 Jan; 395(1):176-90. PubMed ID: 19878682
[TBL] [Abstract][Full Text] [Related]
12. Computational studies of the farnesyltransferase ternary complex part I: substrate binding.
Cui G; Wang B; Merz KM
Biochemistry; 2005 Dec; 44(50):16513-23. PubMed ID: 16342942
[TBL] [Abstract][Full Text] [Related]
13. Molecular dynamics simulations on the critical states of the farnesyltransferase enzyme.
Sousa SF; Fernandes PA; Ramos MJ
Bioorg Med Chem; 2009 May; 17(9):3369-78. PubMed ID: 19369081
[TBL] [Abstract][Full Text] [Related]
14. Crystal structures and small-angle x-ray scattering analysis of UDP-galactopyranose mutase from the pathogenic fungus Aspergillus fumigatus.
Dhatwalia R; Singh H; Oppenheimer M; Karr DB; Nix JC; Sobrado P; Tanner JJ
J Biol Chem; 2012 Mar; 287(12):9041-51. PubMed ID: 22294687
[TBL] [Abstract][Full Text] [Related]
15. Structures of Cryptococcus neoformans protein farnesyltransferase reveal strategies for developing inhibitors that target fungal pathogens.
Hast MA; Nichols CB; Armstrong SM; Kelly SM; Hellinga HW; Alspaugh JA; Beese LS
J Biol Chem; 2011 Oct; 286(40):35149-62. PubMed ID: 21816822
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase.
Hast MA; Fletcher S; Cummings CG; Pusateri EE; Blaskovich MA; Rivas K; Gelb MH; Van Voorhis WC; Sebti SM; Hamilton AD; Beese LS
Chem Biol; 2009 Feb; 16(2):181-92. PubMed ID: 19246009
[TBL] [Abstract][Full Text] [Related]
17. Leveraging Fungal and Human Calcineurin-Inhibitor Structures, Biophysical Data, and Dynamics To Design Selective and Nonimmunosuppressive FK506 Analogs.
Gobeil SM; Bobay BG; Juvvadi PR; Cole DC; Heitman J; Steinbach WJ; Venters RA; Spicer LD
mBio; 2021 Dec; 12(6):e0300021. PubMed ID: 34809463
[TBL] [Abstract][Full Text] [Related]
18. Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release.
Furfine ES; Leban JJ; Landavazo A; Moomaw JF; Casey PJ
Biochemistry; 1995 May; 34(20):6857-62. PubMed ID: 7756316
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents.
Fletcher S; Keaney EP; Cummings CG; Blaskovich MA; Hast MA; Glenn MP; Chang SY; Bucher CJ; Floyd RJ; Katt WP; Gelb MH; Van Voorhis WC; Beese LS; Sebti SM; Hamilton AD
J Med Chem; 2010 Oct; 53(19):6867-88. PubMed ID: 20822181
[TBL] [Abstract][Full Text] [Related]
20. Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity.
Reid TS; Beese LS
Biochemistry; 2004 Jun; 43(22):6877-84. PubMed ID: 15170324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
